TY - JOUR
T1 - An update on targeted therapy in metastatic renal cell carcinoma
AU - Lombardi, Giuseppe
AU - Zustovich, Fable
AU - Donach, Martin
AU - Dalla Palma, Maurizia
AU - Nicoletto, Ornella
AU - Pastorelli, Davide
PY - 2012/5
Y1 - 2012/5
N2 - An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.
AB - An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.
KW - Bevacizumab
KW - Interferon
KW - Renal cancer
KW - Sorafenib
KW - Sunitinib
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84860278682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860278682&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2009.12.018
DO - 10.1016/j.urolonc.2009.12.018
M3 - Article
C2 - 20456985
AN - SCOPUS:84860278682
VL - 30
SP - 240
EP - 246
JO - Urologic Oncology
JF - Urologic Oncology
SN - 1078-1439
IS - 3
ER -